Anthea Wirges is addressing the limitations of durable Chimeric Antigen Receptor (CAR) T cell therapies in hematological malignancies, which suffer from relapses and resistances despite impressive initial response rates. Her solution involves the creation of novel CAR T cells targeting a unique antigen and employing a distinct mode of action to address both the tumor and its supporting microenvironment, aiming to prevent the risk of tumor relapse.
Falling Walls
Falling Walls Science Summit 2023
Login or Register
You need to be logged in to use this feature.
Breaking the Wall of Ineffective CAR-T Cells
Anthea Wirges is Co-Founder and CEO of CARTemis Therapeutics. Since joining the Max Delbrück Center in Berlin as a PhD and later as a PostDoc, she has nearly ten years of experience in the immuno-oncology field with emphasis on improving the therapeutic outcome of CAR T cell therapy. Her work resulted in the invention and patenting of the cytoltyic enhancer technology to boost T cell efficacy. Anthea holds a degree in biochemistry and molecular biology from the University of Jena.
Further Activities to have a look at